for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Novartis Reports Additional Positive Data From Cosentyx Trial

Oct 2 (Reuters) - Novartis:

* POSITIVE 52-WEEK PREVENT DATA CONFIRM COSENTYX® EFFICACY IN ADDRESSING ENTIRE AXSPA SPECTRUM

* PHASE III PREVENT STUDY MET 52-WEEK PRIMARY ENDPOINT OF ASAS40, SHOWING A SUSTAINED RESPONSE IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS

* NOVARTIS PLANS FDA SUBMISSION FOR NR-AXSPA, HAVING SUBMITTED TO EMA PREVIOUSLY Source text for Eikon: Further company coverage: (Berlin Speed Desk)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up